Regulatory Approval

Amid a severe shortage of medical dosimetrists, Radformation’s model-free VMAT automation could redefine the economics and workflow of radiation oncology.

A $450 patent error opened Canada to generic semaglutide. Now, Novo Nordisk is using supply chain supremacy to beat back competitors and reclaim the market.

Koning Health’s recent TGA approval for its compression-free breast CT system signals a strategic shift in diagnostic imaging and patient compliance.

Sempresto just cleared a key FDA hurdle for its phone-mounted auto-injector. But can attaching life-saving drugs to consumer tech disrupt the allergy market?

After decades of regulatory gridlock, a breakthrough UV filter finally hits US shelves. Here is how it could end the reign of gray-market K-beauty imports.

Ruger has abruptly dropped its anti-takeover poison pill. Helen Davis deconstructs the regulatory and strategic forces behind this transatlantic firearms alliance.

IASO208’s FDA clearance marks a critical leap for in vivo CAR-T therapy, promising to strip away manufacturing bottlenecks and reshape global biopharma.

With a critical mining lease in hand ahead of schedule, Victory Metals' North Stanmore project is accelerating, promising a vital non-Chinese source of rare earths.

GT Biopharma secures FDA clearance for a Phase 1 trial of GTB-5550 in multiple myeloma, a strategic pivot for its TriKE® platform, but the trial's start hinges on securing grant funding.

FDA Fast Track for Kestrel's KST-6051 signals more than just a new drug; it reveals a new strategy in the war on cancer, backed by Big Pharma's billions.

Neurodiagnostic giant Natus Medical is localizing production in China, a strategic pivot forced by policy shifts. This move is a blueprint for MedTech survival.

With a new FDA nod for its rare disease drug Joenja, Pharming offers hope to young children, signaling a strategic shift in how we treat complex genetic disorders.

With FDA approval for its RefluxStop® device, Implantica challenges the GERD treatment status quo, promising better outcomes without debilitating side effects.

From a record-breaking telesurgery spanning 13,600 miles to a life-saving operation on a 45-day-old infant, SS Innovations is rapidly democratizing advanced surgery.

The oncology firm's revenue dips and losses widen, but a strategic shift to hospitals and key regulatory wins may pave the way for long-term growth.

A landmark TGA license for Australia's first viral vector CDMO signals a strategic shift, promising to de-risk supply chains and accelerate advanced therapies.

CityWalk e-Bike has a plan for 25,000 vehicles in two major Chinese cities, but a $15 million funding gap and entrenched giants stand between approval and reality.

An analysis of Chiesi’s H1 results reveals a strategy where strategic acquisitions and deep R&D investment drive both profit and a €6B economic footprint.

With a unique EU certification, this UK firm's dissolvable beads deliver targeted antibiotic combinations, promising to slash revision surgeries and redefine care.

A new advisory firm in Dubai is more than a launch; it's a market signal. ZT Global's unique blend of U.S. operational muscle and GCC financial savvy is built to rewire cross-border investment.